Global Glaucoma Therapeutics Market 2017-2021

  • ID: 4416706
  • Report
  • Region: Global
  • 97 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Akorn
  • Allergan
  • Bausch & Lomb
  • Bayer HealthCare
  • Merck
  • Novartis
  • MORE
About Glaucoma Therapeutics

Glaucoma is an ophthalmic disorder that damages the optic nerves in the eyes. The disease is associated with elevated IOP and over time leads to the damage of the optic nerves, by destroying their cell bodies and delicate fibers. This can lead to partial loss of vision or complete blindness. Increased IOP is majorly due to the build-up of aqueous humor, which circulates in the front of an eye.

The analysts forecast the global glaucoma therapeutics market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global glaucoma therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Glaucoma Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Pfizer
  • Novartis
  • Merck
Other prominent vendors
  • Bayer HealthCare
  • Akorn
  • Bausch & Lomb
  • Santen Pharmaceutical
  • Teva Pharmaceutical
  • VISTAKON
Market drivers
  • Increasing geriatric population leading to higher prevalence rate of glaucoma
  • For a full, detailed list, view the full report
Market challenges
  • Growing popularity of alternative treatment options
  • For a full, detailed list, view the full report
Market trends
  • Rising investment in R&D activities
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akorn
  • Allergan
  • Bausch & Lomb
  • Bayer HealthCare
  • Merck
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: RESEARCH METHODOLOGY

PART 03: INTRODUCTION
  • Market outline
PART 04: MARKET LANDSCAPE
  • Market overview
  • Five forces analysis
PART 05: PIPELINE LANDSCAPE

PART 06: MARKET SEGMENTATION BY DRUG CLASS
  • Global glaucoma therapeutics market by prostaglandin analogs
  • Global glaucoma therapeutics market by beta blockers
  • Global glaucoma therapeutics market by alpha agonists
  • Global glaucoma therapeutics market by carbonic anhydrase inhibitors
  • Global glaucoma therapeutics market by others
PART 07: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas – market size and forecast
  • EMEA – market size and forecast
  • APAC – market size and forecast
  • Market opportunity
PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Competitive scenario
PART 12: KEY VENDOR ANALYSIS
  • Allergan
  • Pfizer
  • Novartis
  • Merck
  • Other prominent vendors
PART 13: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global ophthalmic disorder treatment market
Exhibit 02: Types of glaucoma
Exhibit 03: Factors leading to angle-closure glaucoma
Exhibit 04: Types of secondary glaucoma
Exhibit 05: Global glaucoma therapeutics market snapshot
Exhibit 06: Global glaucoma therapeutics market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Major pipeline molecules by vendors
Exhibit 09: Key clinical trials
Exhibit 10: Global glaucoma therapeutics market by drug class ($ millions)
Exhibit 11: Global glaucoma therapeutics market by drug class 2016-2021
Exhibit 12: Global glaucoma therapeutics market by prostaglandin analogs 2016-2021 ($ millions)
Exhibit 13: Advantages and disadvantages of prostaglandin analogs present in global glaucoma therapeutics market
Exhibit 14: Global glaucoma therapeutics market by beta blockers 2016-2021 ($ millions)
Exhibit 15: Common beta blockers used as glaucoma therapeutics
Exhibit 16: Global glaucoma therapeutics market by alpha agonists 2016-2021 ($ millions)
Exhibit 17: Common alpha agonists used for glaucoma treatment
Exhibit 18: Global glaucoma therapeutics market by carbonic anhydrase inhibitors 2016-2021 ($ millions)
Exhibit 19: Common carbonic anhydrase inhibitors used for glaucoma treatment
Exhibit 20: Global glaucoma therapeutics market by others 2016-2021 ($ millions)
Exhibit 21: Cholinergic agents used for glaucoma treatment
Exhibit 22: Americas – market size and forecast
Exhibit 23: Regional comparison
Exhibit 24: Americas – market size and forecast
Exhibit 25: Americas – Year over year growth
Exhibit 26: A snapshot on eye diseases in US 2014 and 2030
Exhibit 27: Snapshot of economic and healthcare expenditure of US 2014-2015
Exhibit 28: Economic and healthcare snapshot of Canada
Exhibit 29: Top three countries in Americas
Exhibit 30: Economic and healthcare snapshot of Europe 2014
EMEA – market size and forecast
Exhibit 31: EMEA – year-over-year growth
Exhibit 32: Medication scenario for glaucoma in Europe
Exhibit 33: Top three countries in EMEA
Exhibit 34: APAC – market size and forecast
Exhibit 35: APAC – year-over-year growth
Exhibit 36: Top three countries in APAC
Exhibit 37: World population by age group 2015 and 2050
Exhibit 38: Percentage of population aged 60 and above by region 2015 and 2050
Exhibit 39: Non-therapeutic glaucoma treatment
Exhibit 40: Side effects of the commonly used glaucoma medications
Exhibit 41: Need of new drug delivery systems
Exhibit 42: Novel efforts in glaucoma therapeutics market
Exhibit 43: Competitive structure analysis of global glaucoma therapeutics market 2016
Exhibit 44: Allergan: Key highlights
Exhibit 45: Allergan: Strength assessment
Exhibit 46: Allergan: Strategy assessment
Exhibit 47: Allergan: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment
Exhibit 56: Merck: Key highlights
Exhibit 57: Merck: Strength assessment
Exhibit 58: Merck: Strategy assessment
Exhibit 59: Merck: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Akorn
  • Allergan
  • Bausch & Lomb
  • Bayer HealthCare
  • Merck
  • Novartis
  • MORE
New Report Released: – Global Glaucoma Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global glaucoma therapeutics market: Allergan, Pfizer, Novartis, and Merck

Other Prominent Vendors in the market are: Bayer HealthCare, Akorn, Bausch & Lomb, Santen Pharmaceutical, Teva Pharmaceutical, and VISTAKON.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Rising investment in R&D activities. Glaucoma is one of the major reason leading to blindness globally. Many government and non-government-funded R&D activities are going on across the globe. It is expected to expand the genetic information about the disease and also will lead to exploring new treatment opportunities aiming at both prevention and treatment of the disease.”

According to the report, one of the major drivers for this market is Increasing geriatric population leading to higher prevalence rate of glaucoma. The global geriatric population continues to grow at a faster pace due to a number of factors such as rapidly falling fertility rates and growing life expectancy due to better medical facilities. According to the US Census Bureau, in 2015, the older population aged 65 years and above was calculated to be 617 million, it is expected to rise to 1,566 million by 2050.

Further, the report states that one of the major factors hindering the growth of this market is Growing popularity of alternative treatment options. Minimally invasive surgeries are gaining high popularity over other forms of treatment. It is expected to have a huge impact on the glaucoma therapeutics market. Although drugs in the form of eye drops are the first choice of treatment for glaucoma, there has been an inclination toward other forms of treatment available for the disease.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • Pfizer
  • Novartis
  • Merck
  • Bayer HealthCare
  • Akorn
  • Bausch & Lomb
  • Santen Pharmaceutical
  • Teva Pharmaceutical
  • VISTAKON
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll